Carbendazim (CBZ) has been considered as an endocrine disruptor that caused mammalian toxicity in different endpoints. Here, we revealed that oral administrations with CBZ at 100 and 500 mg/kg body weight for 28 days induced hepatic lipid metabolism disorder which was characterized by significant increases of hepatic lipid accumulation and triglyceride (TG) levels in mice. The serum cholesterol (TC), high-density lipoprotein, and low-density lipoprotein levels also increased after CBZ exposure. Correspondingly, the relative mRNA levels of some key genes related to lipogenesis and TG synthesis increased significantly both in the liver and fat. Moreover, the increase in serum IL-1b and IL-6 levels by the treatment of CBZ indicated the occurring of inflammation. Furthermore, the levels of bioaccumulation of CBZ in the liver and gut were very low as compared in the feces, indicating that most of CBZ stayed in gastrointestinal tract and interacted with gut microbiota until excreted. At phylum level, the amounts of the Bacteroidetes decreased significantly in the feces after 5 days CBZ exposure. High throughput sequencing of the 16S rRNA gene V3-V4 region revealed a significant reduction in richness and diversity of gut microbiota in the cecum of CBZ-treated mice. UniFrac principal coordinates analysis observed a marked shift of the gut microbiota structure in CBZ-treated mice away from that of the controls. More deeply, operational taxonomic units' analysis identified that a total of 361 gut microbes were significant changed. In CBZ-treated groups, the relative abundance of Firmicutes, Proteobacteria, and Actinobacteria increased and that of Bacteroidetes decreased. Our findings suggested that CBZ could lead hepatic lipid metabolism disorder and gut microbiota dysbiosis in mice.
Nowadays, exposure to additional 'obesogenic' environmental factors and its possible hazard consequence became interesting and topic research fields. There is growing evidence of a major increase in the impacts of environmental pollutants on fat metabolism and obesity in different test models. For example, Miyawaki et al. (2007) reported that perinatal and postnatal exposure to bisphenol A (BPA) increased the body adipose tissue mass, serum total cholesterol (TC), and triacylglycerol (TG) levels in mice. Penza et al. (2011) demonstrated that the exposure to tributyltin chloride caused a significant increase in fat mass of mice at a dose of 0.5 mg/kg at day 8, and this increase was maintained throughout the experimental period (105 days). More importantly, the liver is not only the most important detoxification organ, but also the major lipogenesis tissue. Thus, the hepatic lipid metabolism was also the target of some environmental pollutes (He et al., 2015) . Our previous study indicated that 5-month chronic exposure to low concentration of 2 pesticides, cypermethrin and atrazine, had the potential to cause lipid metabolic dysregulation and hepatotoxicity in mice (Jin et al., 2014) .
A very encouraging and innovative hypothesis had recently been proposed whereby the gut microbiota could be an important factor affecting metabolism, immune system, and even the development of obesity and diabetes (Cani et al., 2008; Li et al., 2008; O'Hara and Shanahan, 2006; Young et al., 2008; ) of the host. Gut microbiota, as documented in many previous studies, is a complex ecosystem inhabited mainly in our intestine. The number of microbes existed in our body is $10 times more than all human cells and encoded 100-fold more unique genes than the human genome (Ley et al., 2006a) . The variation in our 'other genome', also known as microbiome, may play an even greater role than human genome variation in the pathogenesis of obesity (Le Chatelier et al., 2013) . For example, the contents of Firmicutes and Bacteroidetes were changed significantly in obese individuals when compared with lean individuals (Furet et al., 2010; Ley et al., 2006b) . These changes were probably not a mere consequence of obesity, because the obese phenotype could be transmitted by the gut microbiota transplantation in mice, indicating that gut microbial populations might have an active role in obesity pathogenesis (Turnbaugh et al., 2006 (Turnbaugh et al., , 2008 . The stability and richness of parasitic microbes were depended on the condition of host, but the gut microbiota was vulnerable due to its intimate symbiotic relationship with host. On the one hand, host diet, circadian clock, genotype, age, and sex were all regular factors that contributed to the gut microbiota health (Thaiss et al., 2014; Zhang et al., 2010) . On the other hand, many medicine and environmental pollutions could also put the balance of the gut microbiota into imperil (Cox et al., 2014; Guo et al., 2014; Lu et al., 2014) . Therefore, the gut microbiota represents a potential target of some drugs or environmental chemicals.
Carbendazim (CBZ, methyl 2-benzimidazolecarbamate), a systemic broad-spectrum benzimidazole fungicide, is widely used to control fungal diseases in Brazil, Mexico, and Costa Rica where these are the top 3 sources of orange juice imported into the USA (Buch et al., 2013) , and is also used as a preservative both in agriculture and industry (Veerappan et al., 2012) . In China, CBZ is also one of the most widely used fungicide and the typical pollutants in vegetable field and the residual concentration of CBZ in farmland is about 0.18-1.74 mg/kg soil (Liu et al., 2011; Shen et al., 2009) . Although CBZ was classified as a substance unlikely to present hazard in normal use (the acute oral LD50 for rats is $15 000 and !15 000 mg/ kg/day for mice) by World Health Organization (WHO) (WHO/ IPCS, 1999), it had been found to cause several adverse health effects such as liver oxidative stress, liver hydropic degeneration, reproductive toxicity, and endocrine disruption in different test models (Catalgol et al., 2013; Jiang et al., 2014; Selmanoglu et al., 2001; Yu et al., 2009) . However, whether the employment of CBZ has potential effects on gut microbiota and consequent adverse effects is still unclear. In this study, we investigated effects on lipid metabolism and the gut microbiota caused by oral exposure of CBZ in Institute of Cancer Research (ICR) mice. Our results indicated that the administration of CBZ would lead to gut microbiota dysbiosis, hepatic lipid metabolic disturbance, and inflammation in mice.
MATERIALS AND METHODS
Chemicals. CBZ (CAS No.: 21 221-29-4, purity: !98%) was purchased from Sigma-Aldrich; Acetone (CAS No.: 67-64-1, purity: !99.5%) was purchased from Shuanglinhuagong (Hangzhou, China); HPLC-grade acetonitrile (ACN) (CAS No.: Q/BSYZ02-2006, purity: !99.9%) was purchased from TJSHIELD (Tianjin, China). All chemicals were used as-received.
Animals and experimental design. Totally 45 six-week-old male ICR mice (Mus musculus) were purchased from the China National Laboratory Animal Resource Center (Shanghai, China). All the mice were kept in animal facilities (illumination with strip lights, 200 lux at cage level; 22 6 1 C, 12:12 light:dark). Water and food were available ad libitum. The CBZ were dissolved in acetone and mixed completely in the diet and then evaporated all the acetone. After 1 week, all the mice were divided into 3 groups randomly (n ¼ 15). Then, 2 groups were orally administrated by CBZ (100 and 500 mg/kg/body weight) contained diet every day for 4 weeks. The control group was fed with basic diet. During the whole period of the treatment, water was available ad libitum, while food was available only at night. During CBZ-exposure, feces from each mouse were collected every 2 days. Finally, 7 and 8 mice in each group were killed at days 8 and 28, respectively. All the mice were fasted for 12 h and anesthetized by ether before killing. Livers, epididymal fat, intestine, and cecum contents were quickly removed, immediately frozen in liquid nitrogen, and kept at À80 C until use. Sera were also collected for further measurements. Every effort was made to minimize animal suffering in each experiment. All experiments were performed in accordance with the Guiding Principles in the Use of Animals in Toxicology.
Histochemical analyses of the mice liver. Paraformaldehyde-fixed specimens were cut into 5 lm-thick sections and stained for 1 h with 0.1% (w/v) Oil Red O and eosin (H&E). The percentages of Oil Red O-stained and Ballooning degeneration area were determined using an image analyzer (Image pro-Plus 6.0).
Determination of serum and liver index. The serum glucose, TC, high-density lipoprotein (HDL), low-density lipoprotein (LDL), free fatty acids (FFA), TG, hepatic TG, and pyruvate levels were determined using their respective kits purchased from the Nanjing Jiancheng Institute of Biotechnology (Nanjing, China), according to the manufacturer's instructions. For determining hepatic TG levels, the liver was first homogenized with 3 volumes of methanol, and then 6 volumes of chloroform were added and extracted for 16 h at room temperature. The chloroform layer was collected by centrifugation at 3000 Â g for 10 min. For determining hepatic pyruvate levels, the liver was homogenized with 3 volumes of ice cold physiological saline and extracted for 4 h. The water layer was then collected by centrifugation at 3000 Â g for 10 min. The protein contents were determined using a commercial BCA protein kit provided by Sangon Biotech (Shanghai, China).
RNA extraction and real-time quantitative polymerase chain reaction (RT-qPCR). Total RNA in the liver and fat was isolated using TRIzol reagent (Takara Biochemicals, Dalian, China). cDNA was synthesized using a reverse transcriptase kit (Toyobo, Japan). RT-qPCR was performed using the SYBR Green system (Toyobo, Tokyo, Japan) in an Eppendorf MasterCycler ep RealPlex 2 (Wesseling-Berzdorf, Germany). The sequences of the primers were shown in Supplementary Table S1 . The levels of 18SRNA transcripts were determined for reference as a housekeeping gene. The following PCR protocol was adopted: denaturation for 1 min at 95 C, followed by 40 cycles of 15 s at 95 C and 1 min at 60 C. The PCR protocol and the relative quantification of gene expression among the groups were performed as previously described (Jin et al., 2010 (Jin et al., , 2014 .
Determination of serum IL-1b and IL-6. The levels of IL-1b and IL-6 in the serum of each mice were determined by the corresponding mouse ELISA kits (RapidBio, USA) according to the manufacturer's instruction. The ELISA assays were measured on a microplate reader (Power wave XS, Bio-TEK, USA) by using 96-well micro well plate.
DNA extraction, PCR amplification, quantification, and sequencing. Microbial genome DNA was extracted from frozen caecum contents and fecal pellets using the e.Z.N.A. stool DNA kit (OMEGA bio-tek, USA) following the manufacturer's instructions. The resultant DNA was quantified by ultraviolet spectroscopy and then stored at À80 C for further analysis. The V3-V4 region of the 16S rRNA gene was PCR-amplified from microbial genome DNA using primers (forward primer, 5 0 -ACTCCTACGGGAG GCAGCAG-3 0 ; reverse primer, 5 0 -GGACTACHVGGGTWTCTA AT-3 0 ). The PCR products were detected using dual-indexing amplification and sequencing approach on the Illumina MiSeq platform and then using QIIME (vision 1.6.0) to reveal the gut microbiota change. In addition, part of microbial genome DNA was amplified by a RT-qPCR with bacterial phyla specific primers (Chao et al., 2012; Engevik et al., 2013) (Supplementary Table S2 ). The PCR procedures were 50 C for 2 min, 95 C for 10 min; 95 C for 15 s, 56 C for 30 s, and 72 C for 1 min, repeat for 40 cycles; and 72 C for 10 min.
Determination of CBZ residues in the liver, intestine, and feces. An HPLC instrument (SPD-20AV, SHIMADZU) equipped with a UV detector was used to determine the bioaccumulation of CBZ in the liver, intestine, and feces. Separation was carried out on a C18 column (150 mm Â 4.6 mm id, 5 mm particle size). Standard stock solutions containing 1000 mg/ml of CBZ were prepared by dissolving the required amounts of the standard in DMSO and then diluted into required concentration. Four examples were selected randomly from each group and then extracted by HPLC-grade ACN. Because the sample of intestine was small, the 4 intestines from each group were mixed as 1 sample. In brief, tissues and fecal samples were soaked in HPLC-grade ACN and then ultrasonic shattered using Tissuelyser-48. All the extractions were passed through microporous nylon filters with the pore sizes of 0.45 mm in diameter before determination. Analytes were eluted by a mixture of ACN and water (40/60, vol/ vol) at a flow rate of 1 ml/min. CBZ was monitored at 286 nm. To confirm the retention time of CBZ in each tissue extraction, a control with standard CBZ of each type of sample was used and then compared with single corresponding control sample. All the results were analyzed using the software of Labsolutions (SHIMADZU).
Data analysis.
Values are expressed as the mean 6 SEM. Data were evaluated by a 1-way ANOVA followed by Dunnett's or Fisher's Protected Least Significant Difference test using SPSS 13.0 (SPSS, Chicago, Illinois). The data of each CBZ-treated group were compared with the control group, respectively.
RESULTS

Effects of CBZ on Growth Phenotypes
Compared with the control, no significant change in body weights was observed in CBZ-treated mice throughout the 28-day exposure (Fig. 1A) . The relative liver and fat weights to the body weight were also not impacted by the CBZ administration (Figs. 1B and 1C) . However, the Oil Red O or H&E stain still showed some histopathological changes in 2 CBZ-treated groups (Fig. 1D ). Lipid accumulation (Figs. 1D and 1E ) and ballooning degeneration rate (Figs. 1D and 1F) were also significant higher than those in the control group.
Effects of CBZ on the Serum and Liver Index
The levels of serum fasting TC and HDL increased significantly in the animals treated with CBZ for 28 days, but the levels of serum glucose, FFA, TG, and LDL did not change both in 2 CBZtreated groups (Table 1 ). In the liver, TC and TG levels increased significantly in the CBZ-100 group and the CBZ-500 group, respectively, when compared with respective one of the control groups (Table 1 ). In addition, CBZ exposure did not alter the hepatic level of pyruvate.
Effects of CBZ on the Transcription of Genes Related to Lipid Metabolism and Lipoprotein Synthesis in the Liver
The de novo synthesis of FFA was regulated by a number of key upstream transcriptional factors and their downstream genes. As shown in Figure 2 , the transcriptional level of sterol regulatory element binding transcription factor 1 (Srebp1), lysophosphatidic acid acyltransferase-beta (Lpaat-2) and forkhead box A2 (Foxa2), which acts as the regulator of the metabolism of TC and lipid, were increased significantly after the treatment of CBZ. The mRNA level of acetyl-CoA carboxylase 1 (Acc1) (a main downstream gene of FFA synthesis) was increased greatly in the CBZ-500 group. The mRNA levels of diacylglycerol acyltransferase 1 (Dgat1) and diacylglycerol acyltransferase 2 (Dgat2), which are mainly responsible for TG synthesis in the liver, increased significantly after a 28-day CBZ exposure (Fig. 2) . In addition, in cases of some selected genes involved in glycolysis, FFA transport, lipoprotein synthesis, and b-oxidation, similar results were observed. Interestingly, we also observed that the key genes related to the fatty acid and lipid metabolism including Acc1, Acl, Fas, Gpat, and Dgat1 in the epididymal fat increased significantly in 500 mg/kg CBZ-treated group (Supplementary Fig. S1 ).
Effects of CBZ on the Development of Inflammation
Oral exposure of 500 mg/kg CBZ significantly increased the serum concentrations of 2 proinflammatory cytokines IL-1b and IL-6 (Figs. 3A and 3B) . Correspondingly, the mRNA levels of IL-1b and IL-6 in the liver were also significant up-regulated when exposed to 100 and 500 mg/kg CBZ (Fig. 3C) . However, in the fat tissues, only the expression of IL-1b in the CBZ-500-treated group increased significantly as compared with that of the control group (Fig. 3D) .
Effects of CBZ on the Overall Structure of Gut Microbiome
Microbial genome was extracted from cecal contents and feces and analyzed by the Illumine MiSeq or RT-qPCR. RT-qPCR revealed that CBZ treatment caused a significant decrease in phylum Bacteroidetes and significant increases both in Firmicutes and Actinobacteria (Figs. 4A-C) . The relative abundance of aProteobacteria in the cecal content decreased after 7-day 500 mg/ kg CBZ exposure, while it increased significantly when the exposure time extended to 28 days (Fig. 4D) . As for the relative levels of b and c -Proteobacteria, significant increases were also observed in the group treated with 500 mg/kg CBZ for 7 days (Supplementary Figs. S2A and S2B) . To confirm the above findings from RT-qPCR, a high throughput sequencing of the 16S rRNA gene V3-V4 region was used for a deep analysis of the gut microbiota samples. A total of 420 892 usable reads were obtained from all cecal samples and delineated into 5739 operational taxonomic units (OTUs) at the 97% similarity level with the Greengenes OTUs reference sequences. Among them, Firmicutes, Bacteroidetes, Proteobacteria, TM7, and Actinobacteria were the most abundant phyla, being 67.0, 20.0, 7.1, 1.7, and 0.7% of all identified OTUs, respectively. The composition at the phylum level from OTUs was dramatically changed by the treatment of 500 mg/kg CBZ for 28 days (Fig. 4E) , being in accord with the results obtained by RT-qPCR. Finally, we further examined excrete microbiota in the feces during the exposure. During the first 3 days of CBZ exposure, both of the main constituents of microbiomes, Firmicutes and Bacteroidetes, tended to decrease (Fig. 4F) . From 5th day of the CBZ-treatment, Bacteroidetes kept this decreasing direction and finally displayed significant decreases, while Firmicutes were reversed to exhibit increasing trends (Fig. 4F) .
CBZ-Induced Gut Microbiota Changes
In total, 361 of the 3271 identified OTUs were changed significantly by 500 mg/kg CBZ exposure, and among them 250 OTUs decreased and 111 OTUs were enriched. The composition of the gut microbiome at the family level revealed by OTUs showed some more detail changes on mice microbes (Fig. 5A) . The increased OTUs mainly included Desulfovibrionaceae, Ruminococcaceae, Lachnospiraceae, and Deferribacteraceae, while the decreased ones were greatly dominated by S24-7, Paraprevotellaceae, Rikenellaceae, Prevotellaceae, Bacteroidaceae, Porphyromonadaceae, and Christensenellaceae. UniFrac principal coordinates analysis (PCoA) and the ANOSIM analysis together revealed that the gut microbiota structure changed significantly (P ¼ .027) in response to the CBZ administration (Fig. 5B,  Supplementary Figs . S3A and S3B), which was confirmed by unweighted pair-group method with arithmetic means (Supplementary Fig. S3C ). The richness of the gut microbiota was significantly reduced by the CBZ-treatment as revealed by Chao1 estimates (Fig. 5C) . Consistent with the Chao1 estimates, Shannon-Wiener diversity index indicated that the The presented values are the means 6 SE (n ¼ 8). An asterisk indicates a significant difference (*P < .05) between the control-and CBZ-treated groups.
CBZ-treatment relatively (P ¼ .097) decreased the bacterial diversity of the gut microbiota ( Supplementary Fig. S3D ). The mainly identified OTUs at the genus level were shown in Figure 5D .
Bioaccumulation of CBZ in the Liver, Intestine, and Feces
Because some histopathological changes occurred in the CBZtreated group, we further determined the hepatic, intestinal, and fecal levels of CBZ residue using high-performance liquid chromatography (HPLC). Analysis of CBZ, extracted from liver and feces, under optimized condition resulted in a separate peak with retention times of 3.2 min (Figs. 6A and 6B). Calibration curves were obtained from the analysis of the ACN diluted CBZ standards at various concentrations, the linear equations were
for liver, Y(mg/g) ¼ 3 Â 10 À11 X(A), R 2 ¼ 0.99602 for intestine, and
The contents of CBZ in the liver, intestine, and feces increased in a dose-dependent manner in all CBZ-treated groups. The CBZ contents in 100 and 500 mg/kg CBZ-treated groups reached to 0.05 and 0.38 mg/g liver weight, respectively (Fig. 6C) . As for the CBZ in the feces, its levels in the 100 and 500 mg/kg CBZ-treated groups reached to 0.19 and 0.29 mg/g feces weight, respectively (Fig. 6D) . The contents of CBZ in the intestine were similar to those in the liver (Fig. 6E) . Interestingly, the level of CBZ in the feces was about 1000-fold higher than those in the liver or intestine. studies mainly focused on the toxicity of specific organisms, such as the liver and reproductive system (Akbarsha et al., 2000; Rama et al., 2014) . To our knowledge, this is the first study to explore the effects of CBZ on the lipid metabolism and gut microbiota in mice. In our study, the administration of CBZ at doses of 100 and 500 mg/kg body weight indeed led to hepatic histopathological changes, lipid metabolism disorder, and gut microbiota dysbiosis in mice.
In this study, we observed that the lipid accumulation (Figs. 1D and 1E ), TG levels (Table 1) , and hepatic ballooning degeneration rate in the liver significantly increased both in the 2 CBZ-treated groups (no significant between 2 treated groups), indicating that CBZ disturbed lipid metabolism and damaged the liver. Moreover, the significant increase of TC levels in the administrated mice (Table 1) revealed the endocrine disrupting role of CBZ (Novais et al., 2012) . In general, hepatic lipogenesis is mainly regulated by several genes (Nguyen et al., 2008) . The additional accumulation of hepatic lipid and TG might be executed from the differentially expressed genes involving in the metabolism of fatty acid and lipids. Focusing on pathways related to the fatty acid metabolism and lipid metabolic processes, 18 of all the observed genes (totally 30 genes) were differentially expressed between the CBZ-treated and the control mice (Fig. 2) . When all of these changed genes mapped to murine hepatic metabolic pathways, there were consistent with the changes in the same direction for several pathways, including lipogenesis and triglyceride (TG) synthesis, and such phenomenon was also observed in 7-days CBZ-treated mice (Supplementary Fig. S1A ). Interestingly, although the genes related to the serum FFA transport to the liver were upregulated, the serum FFA level was not changed. The consumed fat acid in the liver might derive from the additional exported fat acid which was synthesized in the fat (Supplementary Fig. S1B ). In many cases, the Ppar-c was played an active role in the regulation of genes involved in the lipogenic pathways (Jia et al., 2015) , but the mRNA levels of Ppar-c were not affected by the CBZ both in the liver and the fat whereas lipid accumulated in the liver. The significant upregulated Srebp1c indicated that CBZ might influence the lipid metabolism disorder via disturbing other upstream transcriptional factors. These results clearly indicated that these main transcriptional factors and downstream genes might play very important roles in CBZ induced hepatic lipid accumulation in mice.
In addition, our study also revealed that serum IL-6 and IL1b increased significantly in all CBZ-500-treated groups (Figs. 3A  and 3B ), indicating the development of the inflammation. Tying with serum interleukin change, the relative mRNA levels of IL-6 and IL-1b also enhanced significantly in the liver (Fig. 3C) . In many cases, the inflammation was considered as an accomplice to the development of obesity. The close relationship between metabolic syndrome and inflammation was widely accepted (Arruda et al., 2014) . Thus, our results suggested that the CBZ activated immune system through inflammatory factors, which may be an indirect reason for leading to hepatic lipid metabolism disorder.
These above-mentioned genic and interleukin changes happened in the liver and serum of mice may be caused by the direct contact between the gut and CBZ. However, the HPLC results (Figs. 6C-E) indicated that only a little part of the administrated CBZ was absorbed and transferred into the liver and gut, suggesting that most of CBZ might remain in gastrointestinal tract and interacted with the gut microbiota until excreted. In fact, its levels in the 500 mg/kg CBZ-treated group even reached to 0.29 mg/g feces weight. Because the great fungicidal efficiency of CBZ exhibited in agriculture, we speculated that the disorder of parasitic microbes in mice after the treatment with CBZ for 28 days might, at least partly, be the sterilization of CBZ brought to the gut microbiota and then disturbed the symbiotic relationship in microbial and host.
A large number of evidence indicated that the gut microbiota played an essential role in modulating host metabolism and the development of inflammation (Al-Lahham et al., 2012; Manichanh et al., 2012) , and part of them further suggested that some key functional members of the gut microbes influenced host metabolism and health (Nicholson, 2006; Nicholson et al., 2005) . As a result, the metabolic phenotype variation may associate with the altered microbes even at the species level (Eckburg et al., 2005; Li et al., 2008) . In this study, CBZ significantly increased the abundances of Firmicutes, Proteobacteria, and Actinobacteria, and reduced the abundance of Bacteroidetes (Fig. 4 and Supplementary Fig. S2 ). According to a previous study, the increase of Firmicutes and the decrease of Bacteroidetes in caecum might contribute to the development of the obesity of host (Ley et al., 2005) . The abundant change of the 2 main dominant bacteria in caecum, Firmicutes and Bacteroidetes, may affect the host energy metabolism efficiency. In addition, the autochthonous main flora dysbiosis might affect the intestinal bioisolation of transient biota and finally lead to morbigenous microbe infection (Ingraham and Ingraham, 2000) . Thus, the imbalance in the gut microbiota structure, as indicated in our study, may also contribute to our above-mentioned symptoms. A previous study reported that the gut microbiota could interfere with the host energy metabolism through the upregulation of some key genes such as Acc1, Fas, Chrebp, and Srebp1 (Bä ckhed et al., 2004) . Although CBZ could also induce hepatic lipid metabolism through the upregulation of some key genes including Acc1, Chrebp, and Srebp1, the actually relationship between the gut microbiota changes and lipid accumulation in host is still unclear. In addition, it has also been reported that the structural changes of the gut microbiota, especially the increase of some morbigenous microbes, would cause some serious damage to the host. For example, after CBZ exposure, the dramatic increased Desulfovibrionaceae which was highly related to the occurrence of host inflammation (Cani et al., 2008; Loubinoux et al., 2000; Porschen and Chan, 1977) , could lead to gut barrier function damage and, finally, resulted in host inflammation and metabolic disorder (Zhang et al., 2012) . Moreover, Lachnospiraceae was reported to involve in the development of host hepatic cirrhosis and colorectal cancer (Qin et al., 2014; Zackular et al., 2014) . Beside the harmful bacteria injection, the lose of probiotics, such as Christensenellaceae, which played an important role in reduce host additional body weight gain (Goodrich et al., 2014) , might also lead host energy metabolism into disorder. Furthermore, the analysis of fecal microbial gene (Fig. 4F) , as witness of the gut microbiota changes, proved a definite secondary evidence for the gut microbial dysbiosis. The abundances of Firmicutes and Bacteroidetes were significantly changed by the treatment with CBZ even for 1 week, indicating that the dysbiosis in the gut induced by CBZ was rapid and abiding. The persistent microbiota imbalance accompanied with the CBZ administration might, at least partly, be the cause of the chronic inflammation in all the treated mice and finally induce host metabolism disorder.
In another angle, if considering our humans as a bioactivity container of human metagenome and our 'other genome', previous reports had indicated that the richness of human gut microbiome might be also correlated with obese and inflammatory phenotype. For example, when compared with high bacterial richness individuals, the low bacterial richness (23% of the population) owners are characterized by more marked overall adiposity, insulin resistance, dyslipidaemia, and a more pronounced inflammatory phenotype (Le Chatelier et al., 2013) . Alpha ( Fig. 5C and Supplementary Fig. S3D ) and beta ( Fig. 5B and Supplementary Fig. S3C ) diversity results in this study, conforming to the above-mentioned suggestion, revealed the same phenomenon. Taken together, the alteration of the gut microbiota after CBZ administration may contribute to the host hepatic lipid metabolism disruption and inflammation in some unclear ways.
Our humans are 'super-organisms' composed by 10% human cells and 90% microbial cells. In a symbiotic manner, each part could work harmoniously together. A large amount of evidence indicated that there was a strong relationship between the liver and gut. The contents absorbed from the gut through the portal   FIG. 4 . Overall structure changes in gut microbiota after CBZ treatment. A-D, The relative abundance of Bacteroidetes, Firmicutes, Actinobacteria, and a-Proteobacteria in cecal contents after 7 and 28 days CBZ exposure. E, The cecal microbiome composition profiles at the phylum level in the control group and CBZ-500 (28 days) treated group (each color represents one bacterial phylum). Rare taxa were removed from the legend, but still included in the graph. F, The relative abundance variation of fecal Bacteroidetes and Firmicutes throughout 28 days exposure. Asterisk indicates a significant difference (*P < .05, **P < .01) between control-and CBZ-treated groups. The presented values are the means 6 SE (n ¼ 8).
venous system may affect liver functions, and the liver, in turn, affects intestinal functions through its secreta (Cammarota et al., 2014) . For this reason most of previous researches regarding the gut microbiota were mainly focused on diet and drugs that existed in our daily life normally and obviously. Although the modulation of the gut microbiota with diet or drugs has been indicated to improve host metabolic phenotypes (Furet et al., 2010; Xie et al., 2011) , the potential threat existed in the environment is still concerning. In summary, the liver histopathological changes and hepatic lipid metabolism disorder showed in our study were induced by the administration of CBZ. In one hand, CBZ disrupted the liver lipid metabolism through upregulating many key genes, and caused liver inflammation response which also contributed to the liver lipid metabolism disorder. In another hand, the unabsorbed CBZ in gastrointestinal tract induced the gut microbiota disbiosis which may contribute to the above 2 histopathological changes (Fig. 7) .
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